pericarditis |
Disease ID | 904 |
---|---|
Disease | pericarditis |
Manually Symptom | (Waiting for update.) |
Text Mined Symptom | UMLS | Name | Sentences' Count(Total Symptoms:5) C0007177 | cardiac tamponade | 34 C0031039 | pericardial effusion | 26 C0018801 | heart failure | 8 C0008031 | chest pain | 8 C0031039 | pericardial effusions | 1 |
Manually Genotype(Total Text Mining Genotypes:0) |
---|
(Waiting for update.) |
All Snps(Total Genotypes:1) | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
snpId | pubmedId | geneId | geneSymbol | diseaseId | sourceId | sentence | score | Year | geneSymbol_dbSNP | CHROMOSOME | POS | REF | ALT |
rs3099844 | 25369137 | 6775 | STAT4 | umls:C0031046 | BeFree | The genotype/phenotype correlation analysis showed several associations including a higher risk to develop pericarditis with STAT4, and an association between HCP5 rs3099844 and anti-Ro/SSA antibodies. | 0.000271442 | 2014 | LOC102725068 | 6 | 31481199 | C | A |
GWASdb Annotation(Total Genotypes:0) | |
---|---|
(Waiting for update.) |
GWASdb Snp Trait(Total Genotypes:0) | |
---|---|
(Waiting for update.) |
Mapped by lexical matching(Total Items:0) |
---|
(Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
---|
(Waiting for update.) |
Chemical(Total Drugs:15) | |||||||||
---|---|---|---|---|---|---|---|---|---|
CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
C0031046 | amikacin | D000583 | 37517-28-5 | pericarditis | MESH:D010493 | therapeutic | 20622739 | ||
C0031046 | amphetamine | D000661 | 300-62-9 | pericarditis | MESH:D010493 | marker/mechanism | 9889603 | ||
C0031046 | cabergoline | C047047 | 81409-90-7 | pericarditis | MESH:D010493 | marker/mechanism | 19170199 | ||
C0031046 | cefotaxime | D002439 | 63527-52-6 | pericarditis | MESH:D010493 | marker/mechanism | 2041948 | ||
C0031046 | clozapine | D003024 | 5786-21-0 | pericarditis | MESH:D010493 | marker/mechanism | 11870026 | ||
C0031046 | cyclophosphamide | D003520 | 50-18-0 | pericarditis | MESH:D010493 | marker/mechanism | 11041571 | ||
C0031046 | fluorouracil | D005472 | 51-21-8 | pericarditis | MESH:D010493 | marker/mechanism | 2205312 | ||
C0031046 | indomethacin | D007213 | 53-86-1 | pericarditis | MESH:D010493 | therapeutic | 7752506 | ||
C0031046 | methotrexate | D008727 | 1959/5/2 | pericarditis | MESH:D010493 | marker/mechanism | 17520171 | ||
C0031046 | methylphenidate | D008774 | 113-45-1 | pericarditis | MESH:D010493 | marker/mechanism | 19296063 | ||
C0031046 | minoxidil | D008914 | 38304-91-5 | pericarditis | MESH:D010493 | marker/mechanism | 4053985 | ||
C0031046 | propylthiouracil | D011441 | 51-52-5 | pericarditis | MESH:D010493 | marker/mechanism | 11250767 | ||
C0031046 | tramadol | D014147 | 27203-92-5 | pericarditis | MESH:D010493 | marker/mechanism | 15771942 | ||
C0031046 | valproic acid | D014635 | 99-66-1 | pericarditis | MESH:D010493 | marker/mechanism | 11244813 | ||
C0031046 | vancomycin | D014640 | 1404-90-6 | pericarditis | MESH:D010493 | therapeutic | 1835557 |
FDA approved drug and dosage information(Total Drugs:3) | ||||||||
---|---|---|---|---|---|---|---|---|
DiseaseID | Drug_name | active_ingredients | strength | Dosage Form/Route | Marketing Status | TE code | RLD | RS |
MESH:D010493 | daytrana | methylphenidate | 10MG/9HR (1.1MG/HR) | FILM, EXTENDED RELEASE;TRANSDERMAL | Prescription | None | Yes | No |
MESH:D010493 | daytrana | methylphenidate | 10MG/9HR (1.1MG/HR) | FILM, EXTENDED RELEASE;TRANSDERMAL | Prescription | None | Yes | No |
MESH:D010493 | daytrana | methylphenidate | 10MG/9HR (1.1MG/HR) | FILM, EXTENDED RELEASE;TRANSDERMAL | Prescription | None | Yes | No |
FDA labeling changes(Total Drugs:3) | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DiseaseID | Pediatric_Labeling_Date | Trade_Name | Generic_Name_or_Proper_Name | Indications Studied | Label Changes Summary | Product Labeling | BPCA(B) | PREA(P) | BPCA(B) and PREA(P) | Pediatric Rule (R) | Sponsor | Pediatric Exclusivity Granted Date | NNPS |
MESH:D010493 | 6/4/2006 | daytrana | methylphenidate | ADHD | Summary is pending | Labeling | - | P | - | - | Shire | - | FALSE' |
MESH:D010493 | 12/14/2009 | daytrana | methylphenidate | Postmarketing safety study | Information added to Warnings and Adverse Reactions on skin reactions observed in a postmarketing dermal study in pediatric patients | Labeling | - | P | - | - | Shire | - | FALSE' |
MESH:D010493 | 06/29/2010 | daytrana | methylphenidate | ADHD | Expanded pediatric indication to include adolescent patients ages13-17 years The most commonly reported adverse reactions in a trial in patients 13-17 years included appetite decreased, nausea, insomnia, weight decreased, dizziness, abdominal pain, and anorexia. The majority of patients had erythema at the application site Information on PK parameters, Adverse Event profile and clinical studies | Labeling | - | P | - | - | Shire | - | FALSE' |